Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGJNQW)

Drug Name
WY-48989 Drug Info
Synonyms
WY 48989; 136917-40-3; 4-((2-(7-Chloro-2-phenyl-2H-pyrazolo(4,3-c)quinolin-4-yl)ethyl)amino)benzonitrile; 4-[[2-(7-chloro-2-phenyl-2h-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile; Wy-48989; WY-48,989; AC1L307T; SCHEMBL10625720; DTXSID90160006; GYVYUQVVKBZPRY-UHFFFAOYSA-N; 4[[2-(7-Chloro-2-phenyl-2H-pyrazolo[4,3-c]quinolin-4-yl)ethyl]amino]benzonitrile
Indication
Disease Entry ICD 11 Status REF
Rheumatoid arthritis FA20 Terminated [1]
Cross-matching ID
PubChem CID
132006
CAS Number
CAS 136917-40-3
TTD Drug ID
DMGJNQW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Protease unspecific (PRO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Prolastin DMYSCIL Alpha-1 antitrypsin deficiency 5C5A Approved [3]
ONO-3307 DMQGO74 Coagulation defect 3B10.0 Phase 2 [4]
SRD-441 DM5GAC4 Atopic dermatitis EA80 Phase 2 [5]
AZD-2551 DMZQEDY Chronic obstructive pulmonary disease CA22 Phase 1 [6]
AZD-3342 DMUCQPB Chronic obstructive pulmonary disease CA22 Discontinued in Phase 1 [7]
Aprosulate sodium DMRLHNW Coagulation defect 3B10.0 Discontinued in Phase 1 [8]
EP-2060 DMZA5Q4 Solid tumour/cancer 2A00-2F9Z Terminated [9]
CEP-431 DMDH0AM Alzheimer disease 8A20 Terminated [10]
ALP-242 DM592WE Cystic fibrosis CA25 Terminated [11]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protease unspecific (PRO) TTZBFA0 NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003820)
2 Inhibition of interleukin-1 (IL-1) induced neutral proteases from rabbit articular chondrocytes by WY-46,135 and WY-48,989. Agents Actions. 1991 Sep;34(1-2):223-5.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo. Jpn J Pharmacol. 1989 Dec;51(4):455-63.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029807)
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029854)
7 New Drugs and Targets for Asthma and COPD. Trevor T. Hansel, Peter J. Barnes. 2010. Page(227).
8 Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model. Pol J Pharmacol. 1996 May-Jun;48(3):317-22.
9 Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anticancer Agents Med Chem. 2009 May;9(4):437-56.
10 US patent application no. 7,935,815, Imidazoyl pyridine compounds and salts thereof.
11 Oxidation resistant muteins of antileukoproteinase as potential therapeutic agents. Agents Actions Suppl. 1993;42:111-21.